Michael Buckstein, MD, PhD
- ASSOCIATE PROFESSOR | Radiation Oncology
- Radiation Oncology
- Hospital Affiliations
- Mount Sinai Brooklyn
- Mount Sinai Morningside and Mount Sinai West
- New York Eye and Ear Infirmary of Mount Sinai
- Mount Sinai Queens
- Mount Sinai Beth Israel
- The Mount Sinai Hospital
- FPA/Radiation Oncology Associates 212-241-7502 212-241-7502
Michael Buckstein, M.D., Ph.D. is a radiation oncologist specializing in the treatment of gastrointestinal tumors including the esophagus, stomach, pancreas, liver, gall bladder, bile ducts, rectum, and anus as well coronary brachytherapy. He uses many advanced techniques such Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), Stereotactic Body Radiation Therapy (SBRT), and brachytherapy to maximize local control and cure of the cancer while minimizing radiation side effects to healthy tissue.
Dr. Buckstein graduated from Yale University and received both a medical and doctoral degree from the University of Pennsylvania School of Medicine. His Ph.D. dissertation focused on the biochemical changes that affect the growth patterns of cells. He completed his Medical Internship at Long Island Jewish Medical Center and his Residency in Radiation Oncology at the Icahn School of Medicine at Mount Sinai where he served as Chief Resident.
Dr. Buckstein’s primary research focus is attempting to identify causes and limit treatment related toxicity from radiation therapy. In addition to large retrospective reviews identifying factors involved in disease outcomes and toxicity, he is also heavily involved in projects using genomics to identify specific individuals at risk for developing adverse side effects from treatment. He was involved in a novel study identifying genetic factors predictive for the development of erectile dysfunction following radiation for prostate cancer. His work has resulted in multiple presentations at international meetings as well publication in peer reviewed journals.
- Anal Cancer
- Colorectal Cancer
- Esophageal Cancer
- Gallbladder Cancer
- Liver Cancer
- Pancreatic Cancer
- Radiation Therapy
PhD, University of Pennsylvania School of Medicine
MD, University of Pennsylvania
MD, University of Pennsylvania School of Medicine
Residency, Internal Medicine
Long Island Jewish Medical Center
Residency, Radiation Oncology
Mount Sinai Hospital
Roentgen Resident Research Award
Radiological Society of North America
Awarded for outstanding research during residency
Best of ASTRO Award
New York Roentgen Society
Elected as a best abstract from the New York area at ASTRO 2011
John G. Clark Prize
University of Pennsylvania School of Medicine
Awarded for outstanding research during medical school
Medical Scientist Training Program Fellowship
National Institutes of Health
Fellowship to support PhD work during medical school
Outcomes Based Research for Gastrointestinal Malignancies
Using a variety of tools institutional and national based databases, Dr. Buckstein is involved with research attempting to identify treatment related predictors for outcomes and development of treatment related toxicities. He has a particular focus on understanding outcomes with patients who have Inflammatory Bowel Disease who develop a malignancy.
Identifying Genetic Predictors for Radiation Treatment Related Toxicity
Dr, Buckstein is involved in mutliple projects using Genome-Wide Association Studies (GWAS) to identify individual genetic differences that might predict for the development of radiation toxicity. This will ultimately allow physicians to personalize therapy to each individual, potentially minimizing toxicity and optimizing therpeutic outcomes.
Use of Stereotactic Body Radiation Therapy and Hepatocellular Carcinomas
Dr. Buckstein is the principal investigator on a study using combination trans-arterial chemo embolization (TACE) with stereotactic body radiation therapy (SBRT) as a treatment paradigm for treating large hepatocellular carcinomas. In addition, he is actively working to safely integrate SBRT into treatment paradigms for HCC.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Buckstein did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.